By establishing a significant association between DPYD gene variants and platin resistance in NSCLC patients, our study strongly advocates for the integration of genetic testing into clinical protocols, ultimately enhancing patient outcomes in the realm of platin-based chemotherapy. Here, DPYD is linked to non-small cell lung carcinoma.